Literature DB >> 17472848

Increased complication rates of cardiac rhythm management devices in ESRD patients.

Arijit Dasgupta1, Jessica Montalvo, Sara Medendorp, Donald M Lloyd-Jones, Cybele Ghossein, Jeffrey Goldberger, Rod Passman.   

Abstract

BACKGROUND: Patients with end-stage renal disease (ESRD) have a high incidence of sudden cardiac death and may benefit from implantable cardioverter defibrillators (ICDs). However, ESRD also may predispose patients to device-related complications, potentially offsetting some of the benefits of prophylactic ICD placement. The purpose of this study is to compare the incidence of complications after cardiac rhythm management device (CRMD) implantation in patients with and without ESRD.
METHODS: An observational study was performed on 41 patients with ESRD and 123 controls without ESRD who had a CRMD (permanent pacemaker or ICD) implanted at a single institution from 1998 to 2005. Controls were matched for age, sex, type of device, and calendar year of device implantation. Primary and secondary end points were any complication and complications requiring intervention, respectively.
RESULTS: 23 complications occurred in 16 of 41 patients with ESRD (39%) versus 13 complications in 13 of 123 matched controls (11%; P < 0.001). Major complications occurred in 29% of patients with ESRD versus 5% of controls (P < 0.001), whereas minor complications occurred in 17% and 6%, respectively (P < 0.03). Hematoma, thrombosis, and device-related complications, including elevated defibrillation thresholds, were more common in patients with ESRD (P < 0.05 for all), and there also was a nonsignificant trend toward greater infection risk (P = 0.1). There were no fatal complications in either group.
CONCLUSIONS: Patients with ESRD had greater complication rates after CRMD implantation compared with matched controls, but these complications did not result in death. These results should be considered when evaluating patients with ESRD for prophylactic CRMD implantation, but do not support withholding such therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17472848     DOI: 10.1053/j.ajkd.2007.02.272

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  29 in total

Review 1.  Sudden cardiac death in chronic kidney disease: epidemiology and prevention.

Authors:  M Khaled Shamseddin; Patrick S Parfrey
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

2.  Implantable electrophysiologic cardiac device infections: a risk factor analysis.

Authors:  D Raad; J Irani; E G Akl; S Choueiri; E Azar; J Abboud; C Afif
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-25       Impact factor: 3.267

3.  Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.

Authors:  Patrick H Pun; Anne S Hellkamp; Gillian D Sanders; John P Middleton; Stephen C Hammill; Hussein R Al-Khalidi; Lesley H Curtis; Gregg C Fonarow; Sana M Al-Khatib
Journal:  Nephrol Dial Transplant       Date:  2014-11-17       Impact factor: 5.992

4.  Dialytic interval and the timing of electrocardiographic screening for subcutaneous cardioverter-defibrillator placement in chronic hemodialysis patients.

Authors:  Cindy You; Shishir Sharma; Aakash Bavishi; Christopher A Groh; Yazan Alia; Basil Saour; Rod Passman
Journal:  J Interv Card Electrophysiol       Date:  2018-03-10       Impact factor: 1.900

Review 5.  The interplay between CKD, sudden cardiac death, and ventricular arrhythmias.

Authors:  Patrick H Pun
Journal:  Adv Chronic Kidney Dis       Date:  2014-10-24       Impact factor: 3.620

6.  Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United States from 2003 to 2013.

Authors:  Seyed Mohammadreza Hosseini; Kasra Moazzami; Guy Rozen; Jeena Vaid; Ahmed Saleh; Kevin E Heist; Mark Vangel; Jeremy N Ruskin
Journal:  Eur Heart J       Date:  2017-07-14       Impact factor: 29.983

7.  Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients.

Authors:  Matthew J Kolek; William F Dresen; Quinn S Wells; Christopher R Ellis
Journal:  Pacing Clin Electrophysiol       Date:  2012-12-17       Impact factor: 1.976

8.  The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy.

Authors:  David D Daly; Anbukarasi Maran; J Madison Hyer; Frederick Funke; Ashley Waring; Frank A Cuoco; J Lacy Sturdivant; Robert B Leman; Michael R Gold
Journal:  Pacing Clin Electrophysiol       Date:  2016-06-07       Impact factor: 1.976

9.  Efficacy of a Bio-Absorbable Antibacterial Envelope to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Subjects.

Authors:  Matthew J Kolek; Neel J Patel; Walter K Clair; S Patrick Whalen; Jeffrey N Rottman; Arvindh Kanagasundram; Sharon T Shen; Pablo J Saavedra; Juan C Estrada; Robert L Abraham; Christopher R Ellis
Journal:  J Cardiovasc Electrophysiol       Date:  2015-09-06

10.  Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis.

Authors:  Patrick H Pun; Craig S Parzynski; Daniel J Friedman; Gillian Sanders; Jeptha P Curtis; Sana M Al-Khatib
Journal:  Clin J Am Soc Nephrol       Date:  2020-09-23       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.